Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research

Illumina (NASDAQ:ILMN) unveiled a distributed whole-genome sequencing MRD research solution, enabling labs to study molecular residual disease in solid tumors and blood cancers.

Rhea-AI Summary

Illumina (NASDAQ:ILMN) unveiled a distributed whole-genome sequencing MRD research solution, enabling labs to study molecular residual disease in solid tumors and blood cancers. The NovaSeq-compatible workflow delivers tumor fingerprinting and blood-based MRD detection in as fast as 5 days, with analytical sensitivity down to 10 ppm and a ctDNA algorithm showing 99.5% analytical specificity. Early access is available now, with global launch planned next year and an ultra-sensitive single-digit ppm duplex-based workflow in development.

Positive

• End-to-end MRD workflow turnaround in as fast as 5 days
• Analytical sensitivity optimized down to 10 ppm for MRD detection
• DRAGEN ctDNA algorithm reports 99.5% analytical specificity
• Supports both solid tumor fingerprinting and blood-based MRD on NovaSeq systems
• Early-access MRD solution today with global launch targeted for next year
• Roadmap to duplex-based, single-digit ppm MRD workflow in development

Negative

• Current MRD solution limited to research use, not standard clinical care
• Ultra-sensitive duplex MRD workflow remains under development, not yet available
• Commercial success depends on NovaSeq X updates and customer adoption

Argus May 28 session

+5.68% close to close Open Argus

Details

News Market Reaction – ILMN

On May 28, the day this news came out, ILMN closed 5.68% above the previous close.

Data tracked by StockTitan Argus for the May 28 session.

Key Figures

Workflow duration: 5 days Analytical sensitivity: 10 ppm Analytical specificity: 99.5% +5 more

Workflow duration

5 days

End-to-end MRD research workflow completion time

Analytical sensitivity

10 ppm

MRD solution optimized detection level for early-stage, low-shedding tumors

Analytical specificity

99.5%

ctDNA detection algorithm specificity distinguishing tumor signal from noise

NovaSeq X output

35B

NovaSeq X output used as foundation for new MRD workflow

Quality scores

Q70

NovaSeq X quality scores underlying MRD workflow performance

Planned ultra-sensitivity

Single-digit ppm

In-development duplex-read workflow targeting ultra-sensitive MRD detection

ASCO 2026 poster time

9:00 a.m.–12:00 p.m.

Poster session with Bristol Myers Squibb on May 31, 2026

ASCO abstract ID

8591

Abstract identifier for joint MRD-related poster

Historical Context

5 past events · Latest: May 21

5 events

1. May 21

   Board appointment

   24h Move

   -0.3%

   Election of David P. King to board, adding diagnostics and regulatory expertise.

2. May 19

   CSR report

   24h Move

   -0.8%

   Release of 2025 Corporate Responsibility Report highlighting access, equity, and impact.

3. Apr 30

   Earnings, guidance

   24h Move

   +7.1%

   Q1 FY2026 beat with revenue growth, strong margins, raised guidance, and buyback.

4. Apr 16

   Product upgrade

   24h Move

   +0.3%

   Launch of DRAGEN v4.5 expanding germline, oncology, multiomic capabilities.

5. Apr 14

   Data partnership

   24h Move

   +2.6%

   Partnership to analyze 100,000 pediatric whole genomes via cloud platform.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

molecular residual disease, whole-genome sequencing, circulating tumor DNA, ctDNA, +4 more

8 terms

molecular residual disease medical

"In precision healthcare, early and accurate detection of molecular residual disease is critical..."

Molecular residual disease is the tiny amount of cancer that can remain in the body after treatment and is detectable only by sensitive tests that find cancer DNA or other molecular traces. It matters to investors because these measurements can predict relapse, guide whether additional therapy is needed, and shape the market for diagnostics and drugs—much like finding embers after a fire helps decide if more firefighting is required.

whole-genome sequencing medical

"announced a new complete solution for molecular residual disease (MRD) research based on whole-genome sequencing (WGS)."

Whole-genome sequencing is the process of reading an organism’s entire DNA instruction manual to capture all genetic information rather than just selected parts. For investors, it matters because having the full genetic picture can reveal new diagnostics, drug targets, or personalized treatments that drive product value, regulatory approvals, and long-term revenue potential, while improvements in speed and cost can expand market reach like making a complex map easier and cheaper to produce.

circulating tumor DNA medical

"connects each fingerprint to serial circulating tumor DNA (ctDNA), offering customers flexible workflow combinations..."

Fragments of DNA shed by cancer cells into the bloodstream that act like tiny fingerprints of a tumor; they can be detected with a blood test rather than a biopsy. Investors care because circulating tumor DNA (ctDNA) enables faster, lower-cost ways to detect disease, track treatment response, identify emerging resistance and enroll patients in trials—factors that can materially affect the commercial prospects of diagnostics and therapeutics.

ctDNA medical

"to develop and demonstrate a ctDNA detection algorithm with 99.5% analytical specificity..."

Circulating tumor DNA (ctDNA) is tiny fragments of genetic material shed by cancer cells into the bloodstream, like breadcrumbs that can reveal a tumor’s presence and genetic makeup without needing a biopsy. For investors, ctDNA matters because tests and technologies that detect and analyze these fragments can speed diagnosis, track treatment response, and signal relapse, creating commercial opportunities in diagnostics, personalized therapies, and monitoring services.

analytical specificity medical

"ctDNA detection algorithm with 99.5% analytical specificity to distinguish true tumor signals..."

Analytical specificity measures how well a diagnostic test or laboratory assay avoids reacting to substances it should ignore — in other words, how rarely it gives a positive result for the wrong thing. For investors, high specificity means fewer false positives, which lowers the risk of costly recalls, regulatory problems, or damaged reputation and supports clearer market demand for the product, similar to a smoke detector that only alarms for real smoke and not harmless steam.

duplex reads technical

"detection in the single-digit ppm range leveraging duplex reads is currently in development."

Duplex reads are DNA sequencing results where both complementary strands of the same DNA molecule are read and compared so true genetic changes can be confirmed while random errors are discarded. For investors, duplex reads matter because they greatly increase confidence in diagnostic tests and clinical data—like double-checking a receipt on both sides—reducing false positives and making trial outcomes, regulatory decisions, and market claims more credible.

whole-genome kit technical

"the MRD solution is the first whole-genome kit with flexibility to enable solid tumor MRD..."

A whole-genome kit is a packaged set of laboratory reagents and tools that lets researchers read an individual’s entire DNA sequence—the full “instruction manual” of a person or organism. For investors, it matters because these kits enable companies to offer comprehensive genetic testing, drug-target discovery, and precision diagnostics; their quality, cost and regulatory clearance affect a provider’s ability to scale services and generate revenue.

quality scores technical

"Built on recently announced NovaSeq X advancements, including 35B output and Q70 quality scores..."

A quality score is a single-number rating that sums up how reliable, well-run, or healthy an asset, company, dataset, or medical result appears based on a set of measurable criteria. Investors use it like a quick checklist or report card to compare options, spot higher-risk cases, and decide where to focus research or money—similar to choosing a restaurant by star ratings before reading full reviews.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

An advanced research workflow for fast, flexible detection of molecular residual disease during and following treatment

Solution is the first in a new WGS oncology portfolio, building on Illumina's history of leadership as foundation for MRD market

SAN DIEGO, May 28, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced a new complete solution for molecular residual disease (MRD) research based on whole-genome sequencing (WGS). As a distributed kit, it will enable more labs to adopt MRD detection for clinical research. Now in early access for select clinical research partners, the MRD solution is the first whole-genome kit with flexibility to enable solid tumor MRD and blood cancer genomic profiling. It is the first in a new portfolio of WGS oncology research offerings, with additional solutions in development leveraging the latest advancements of the NovaSeq X™.

"In precision healthcare, early and accurate detection of molecular residual disease is critical to monitoring patients during and after cancer treatment," said Todd Christian, senior vice president of Services, Arrays and Genomic Access at Illumina. "Illumina's MRD solution for clinical research leverages the advanced sensitivity of whole-genome sequencing, coupled with unparalleled analysis, to enable our customers to more easily deliver the most precise information to advance MRD research. We aim to make WGS in oncology more accessible and scalable to support the integration of precision solutions into the standard of care."

The MRD solution supports "fingerprinting" through solid tumor samples, and MRD detection using blood samples, all compatible on NovaSeq Systems. The end-to-end research workflow can be completed in as fast as 5 days and is optimized for analytical sensitivity as low as 10 ppm, particularly important for early-stage and low-shedding tumors, including breast, ovarian, and renal.

Illumina's first-of-its-kind DRAGEN™ MRD analysis connects each fingerprint to serial circulating tumor DNA (ctDNA), offering customers flexible workflow combinations to meet their specific needs. Leveraging DRAGEN's unparalleled speed and accuracy, the new MRD solution has been optimized across thousands of samples to develop and demonstrate a ctDNA detection algorithm with 99.5% analytical specificity to distinguish true tumor signals from background noise.

Early adopters see strong performance with Illumina's WGS oncology solution

Several academic institutes evaluated the workflow. Mayo Clinic evaluated the solutionⁱ on a small sample cohort and found high concordance among previously characterized paired samples. The results were also highly correlated with clinical and imaging results over time. The team is planning to expand the cohort for additional research with Mayo Clinic and other academic partners.

"We are looking forward to participating in early access and evidence generation for a tumor-informed, non-bespoke whole-genome sequencing approach to MRD," said Gang Zheng, MD, PhD and professor of Laboratory Medicine and Pathology at Mayo Clinic. "We have seen early pilot results across several solid tumor clinical samples that demonstrated the potential utility of highly sensitive solid tumor MRD detection, and we continue to pilot technologies that help us efficiently progress in our ability to analyze and translate complex genomic arrays." 

Illumina and Bristol Myers Squibb will jointly present a poster at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, May 31, from 9:00 a.m. to 12:00 p.m. (abstract ID 8591, poster board #381, Lung Cancer: Non–Small Cell Metastatic track). More information can be found at this link. 

Roadmap to achieve ultra-sensitivity tailored for broader adoption

Built on recently announced NovaSeq X advancements, including 35B output and Q70 quality scores, a complementary research workflow that will deliver ultra-sensitive MRD detection in the single-digit ppm range leveraging duplex reads is currently in development.

"Illumina continues to push the NovaSeq X's capabilities to help our customers break barriers and unlock more discoveries," said Steve Barnard, PhD, chief technology officer of Illumina. "The new portfolio will bring advanced MRD research directly into labs with unmatched speed and sensitivity. The NovaSeq X is built for the long term, and Illumina will continue to deliver technologies that empower our customers to accelerate oncology breakthroughs."

Illumina technology also fuels centralized MRD providers leading the market today. The NovaSeq X offers foundational capabilities to support the quality, reliability, and scale needed as MRD adoption continues to grow. Illumina's new oncology portfolio builds upon the unique, integrated insight ecosystem of workflows, data and community across genomic, multiomic, and clinical research applications—anchored on the NovaSeq X.

Illumina's MRD research solution is available today for early access to select partners and will launch for global customers next year. Learn more here.  

Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) ⁱⁱour ability to successfully implement NovaSeq X updates on a cost-effective and timely basis, (ii) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (iii) our ability to manufacture robust instrumentation and consumables and develop reliable software solutions; and (iv) the acceptance and adoption by customers of our newly launched or updated products, which may or may not meet our expectations and theirs, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation and do not intend to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Contacts
Investors:
Illumina Investor Relations
858-291-6421
IR@illumina.com

Media:
Christine Douglass
PR@illumina.com

___________________

i As an early user, Mayo Clinic independently executed and evaluated the assay in their lab.

ii As of the Q4 financial disclosures, the NovaSeq X active install base was 890 at the end of FY2025.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-introduces-the-first-distributed-whole-genome-sequencing-solution-for-highly-sensitive-mrd-research-302784511.html

SOURCE Illumina, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Illumina (ILMN) announce about its new MRD research solution in May 2026?

Illumina announced a distributed whole-genome sequencing MRD research solution designed for solid tumors and blood cancers. According to Illumina, the NovaSeq-based workflow offers tumor fingerprinting and blood MRD detection, aiming to make oncology whole-genome sequencing more accessible and scalable for clinical research labs.

How sensitive is Illumina's new MRD workflow for detecting residual cancer (ILMN)?

The MRD workflow is optimized for analytical sensitivity as low as 10 ppm. According to Illumina, its DRAGEN MRD analysis, tuned on thousands of samples, delivers a ctDNA detection algorithm with 99.5% analytical specificity, distinguishing true tumor signals from background noise in early-stage or low-shedding tumors.

When will Illumina's whole-genome MRD research solution (ILMN) be available to global customers?

Illumina's MRD research solution is available now through early access for select partners. According to Illumina, a broader commercial launch for global customers is planned for next year, expanding availability of whole-genome, tumor-informed MRD research directly into more oncology-focused laboratories.

How does NovaSeq X technology support Illumina's new MRD research portfolio (ILMN)?

NovaSeq X provides the sequencing foundation for Illumina's MRD portfolio, including the new workflow. According to Illumina, recent NovaSeq X enhancements such as 35B output and Q70 quality scores underpin both the current solution and an upcoming ultra-sensitive, duplex-based MRD workflow in development.

What roadmap did Illumina outline for ultra-sensitive MRD detection using whole-genome sequencing (ILMN)?

Illumina is developing a complementary research workflow to reach single-digit ppm MRD sensitivity. According to Illumina, this future workflow will leverage duplex reads on NovaSeq X, aiming to deliver ultra-sensitive detection that could broaden adoption of MRD research in oncology-focused laboratories.

What early performance feedback has Illumina received on its WGS MRD solution (ILMN)?

Mayo Clinic reported high concordance between the new workflow and previously characterized paired samples in a small cohort. According to Illumina, results also correlated strongly with clinical and imaging data over time, and Mayo Clinic plans to expand research in collaboration with additional academic partners.